Results 281 to 290 of about 179,384 (308)

Comment on "Association Between Triglyceride- Glucose Index and Prognosis of Patients with Hypertrophic Cardiomyopathy and Heart Failure with Preserved Ejection Fraction". [PDF]

Anatol J Cardiol
Yeter Arslan G.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Heart Failure With Preserved Ejection Fraction: A Review.

JAMA, 2023
Importance Heart failure with preserved ejection fraction (HFpEF), defined as HF with an EF of 50% or higher at diagnosis, affects approximately 3 million people in the US and up to 32 million people worldwide.
M. Redfield, B. Borlaug
semanticscholar   +3 more sources

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.

New England Journal of Medicine
BACKGROUND Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data ...
Milton Packer, M. Zile, Christopher M. Kramer, Seth J. Baum, S. Litwin, V. Menon, Junbo Ge, G. Weerakkody, Yang Ou, Mathijs C Bunck, Karla C. Hurt, Masahiro Murakami, B. Borlaug   +12 more
semanticscholar   +3 more sources

Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.

New England Journal of Medicine
BACKGROUND Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction ...
Scott D. Solomon, John J. V. McMurray, M. Vaduganathan, Brian Claggett, P. Jhund, A. Desai, A. Henderson, C. Lam, B. Pitt, M. Senni, Sanjiv J. Shah, A. Voors, F. Zannad, I. Abidin, M. A. Alcocer-Gamba, John J. Atherton, J. Bauersachs, Changxing Ma, C. Chiang, O. Chioncel, V. Chopra, J. Comin‐Colet, G. Filippatos, C. Fonseca, Grzegorz Gajos, S. Goland, Eva Goncalvesova, Seokmin Kang, T. Katova, Mikhail N. Kosiborod, G. Latkovskis, Alex Lee, G. Linssen, Guillermo Llamas-Esperón, Vyacheslav Mareev, F. Martinez, Vojtěch Melenovský, B. Merkely, Savina Nodari, Mark C. Petrie, C. Saldarriaga, J. F. K. Saraiva, Naoki Sato, Morten Schou, K. Sharma, Richard W. Troughton, Jacob A. Udell, H. Ukkonen, O. Vardeny, Subodh Verma, D. von Lewinski, Leonid Voronkov, M. Yılmaz, S. Zieroth, James Lay‐Flurrie, Ilse van Gameren, F. Amarante, P. Kolkhof, Prabhakar Viswanathan   +58 more
semanticscholar   +3 more sources

Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.

Lancet, The
BACKGROUND Heart failure with mildly reduced or preserved ejection fraction (hereafter referred to as HFpEF) is the most common type of heart failure and is associated with a high risk of hospitalisation and death, especially in patients with overweight,
M. Kosiborod, J. Deanfield, R. Pratley, B. Borlaug, Javed Butler, M. Davies, S. Emerson, S. Kahn, D. Kitzman, I. Lingvay, Kenneth W. Mahaffey, Mark C. Petrie, J. Plutzky, S. Rasmussen, Cecilia Rönnbäck, Sanjiv J. Shah, Subodh Verma, P. E. Weeke, A. M. Lincoff   +18 more
semanticscholar   +3 more sources

Heart failure with preserved ejection fraction.

New England Journal of Medicine, 2006
A. Ahmed, J. Fleg, M. Gheorghiade
semanticscholar   +2 more sources

Dapagliflozin in Heart Failure with Preserved Ejection Fraction

New England Journal of Medicine, 2023
To the Editor: Solomon et al. (Sept. 22 issue)(1) report on the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial, which showed reduced risks of heart failure-related outcomes (hospitalization for heart failure or an urgent visit for heart failure) among patients with a mildly ...
Domenico Gabrielli, Fabrizio Oliva, Giuseppe Zuccala   +2 more
openaire   +6 more sources

Heart failure with preserved ejection fraction

Nature Reviews Disease Primers
Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases and has a prevalence that is expected to rise with the growing ageing population. HFpEF is associated with significant morbidity and mortality.
Carine E. Hamo, Colette DeJong, Nick Hartshorne-Evans, Lars H. Lund, Sanjiv J. Shah, Scott Solomon, Carolyn S. P. Lam   +6 more
  +5 more sources

Heart failure with preserved ejection fraction (diastolic heart failure)

Orvosi Hetilap, 2012
Diastolic heart failure, which is also called as heart failure with preserved ejection fraction, is a clinical syndrome in which patients have signs and symptoms of heart failure, normal or near normal left ventricular ejection fraction (≥50%) and evidence of diastolic dysfunction.
István, Czuriga, Attila, Borbély, Dániel, Czuriga, Zoltán, Papp, István, Edes   +4 more
openaire   +2 more sources

Diagnosing heart failure with preserved ejection fraction

Expert Opinion on Medical Diagnostics, 2013
Heart failure with preserved ejection fraction (HFPEF) is a common syndrome, accounting for about 50% of all patients with heart failure (HF). Morbidity and mortality are similar to patients with HF with reduced ejection fraction (HFREF), yet no effective treatment has been identified in randomized clinical trials.This article provides an overview of ...
Becher, Peter Moritz, Lindner, Diana, Fluschnik, Nina, Blankenberg, Stefan, Westermann, D.   +4 more
openaire   +3 more sources